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Background: Multiple studies demonstrated pro-angiogenic effects of microRNA (miR)-27b. Its targets include Notch
ligand Dll4, Sprouty (Spry)-2, PPARγ and Semaphorin (SEMA) 6A. miR-27 effects in the heart are context-dependent:
although it is necessary for ventricular maturation, targeted overexpression in cardiomyocytes causes hypertrophy
and dysfunction during development. Despite significant recent advances, therapeutic potential of miR-27b in
cardiovascular disease and its effects in adult heart remain unexplored. Here, we assessed the therapeutic potential
of miR-27b mimics and inhibitors in rodent models of ischemic disease and cancer.
Methods: We have used a number of models to demonstrate the effects of miR-27b mimicry and inhibition
in vivo, including subcutaneous Matrigel plug assay, mouse models of hind limb ischemia and myocardial
infarction and subcutaneous Lewis Lung carcinoma.
Results: Using mouse model of myocardial infarction due to the coronary artery ligation, we showed that miR-27b
mimic had overall beneficial effects, including increased vascularization, decreased fibrosis and increased ejection fraction.
In mouse model of critical limb ischemia, miR-27b mimic also improved tissue re-vascularization and perfusion. In both
models, miR-27b mimic clearly decreased macrophage recruitment to the site of hypoxic injury. In contrast, miR-27b
increased the recruitment of bone marrow derived cells to the neovasculature, as was shown using mice reconstituted
with fluorescence-tagged bone marrow. These effects were due, at least in part, to the decreased expression of Dll4,
PPARγ and IL10. In contrast, blocking miR-27b significantly decreased vascularization and reduced growth of
subcutaneous tumors and decreased BMDCs recruitment to the tumor vasculature.
Conclusions: Our study demonstrates the utility of manipulating miR-27b levels in the treatment of cardiovascular
disease and cancer.
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Angiogenesis is a tightly regulated process, which is crit-
ical for organ development and tissue homeostasis in
adults [1]. Deregulated angiogenesis underlies numerous
pathological conditions and represents an important
therapy target [2].
Excessive angiogenesis and vascular leakiness are the
hallmarks of cancer and inflammatory disease and sev-
eral anti-angiogenic agents have been approved for* Correspondence: olgavolp@northwestern.edu
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creativecommons.org/publicdomain/zero/1.0/clinical use [3]. Most of them, like neutralizing anti-
bodies (Bevacizumab, Ranizumab) or decoy receptors
(VEGF trap, Aflibercept), sequester the key angiogenic
factor, Vascular Endothelial Growth Factor (VEGF). The
success of anti-angiogenics is most striking in patients with
age-related macular degeneration where they normalize
the vasculature, curtail vascular leakage/edema and restore
visual acuity [4].
Bevacizumab is FDA-approved for metastatic cancers,
including colon, lung, ovaries and glioblastoma multi-
forme of the brain, where it is used with standard
chemotherapy and significantly improves the outcomes.
However, the use of VEGF-targeting agents is associated
with severe systemic toxicities, which stem from its rolearticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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thromboembolism [5], renal failure [6], intestinal perfor-
ation [7, 8], and neuropathies [9]. Thus, the need remains
for the new, safer anti-angiogenic treatments [10].
On the other hand, pathologic conditions including
peripheral arterial disease (PAD) and myocardial infarc-
tion (MI), in which ischemia causes irreversible tissue
damage could benefit from enhanced angiogenesis and
subsequent accelerated reperfusion and improved tissue
homeostasis [11]. Gene therapy with angiogenic factors
such as VEGF, basic fibroblast growth factor (bFGF) and
hepatocyte growth factor (HGF) was very effective in
preclinical models of critical limb ischemia (CLI) and MI
[12–15]. However, randomized, double blinded placebo
controlled clinical studies showed limited or no improve-
ment [16, 17]. Another approach to revascularization of
ischemic tissue is represented by stem cell-based therap-
ies, which show benefits in clinical and preclinical studies
[18, 19]. However, larger trials are needed to confirm the
improvement of the clinically relevant outcomes.
MicroRNA (miRNA) are rapidly emerging as import-
ant regulators of all aspects of angiogenesis including
vascular sprouting [20, 21], proliferation, survival and
migration [21, 22] of the vascular endothelial cells and
recruitment of the vascular progenitor cells [23]; miRNA
are also involved in maturation of the newly formed
vasculature, by controlling angiopoietin expression [24].
Unlike VEGF inhibitors, miRNA provide a more subtle
degree of regulation whereby they moderately decrease
the expression of multiple target genes involved in the
same or related biological processes [25].
Pro-angiogenic function of miR-27b was demonstrated
in several studies [26–28]. We have shown previously that
miR-27b promotes capillary sprouting and endothelial tip
fate by suppressing the Notch ligand, Delta-like ligand 4
(Dll4) and the negative regulator of branching, Sprouty-2
(Spry-2) [26]. Others have shown that miR-27b also inhibits
Spry-2 and repulsive signaling by Semaphorin 6A [27, 28].
Here, we provide experimental evidence that therapeutic
manipulation of miR-27b can be beneficial in angiogenesis-
dependent disease. Limited local application of miR-27b
mimic was sufficient to restore angiogenesis and improve
tissue function in two models of ischemic disease, hind
limb ischemia, which mimics CLI, and coronary artery
ligation, a MI model. Importantly, miR-27b increased the
recruitment of bone marrow derived cells (BMDCs) to the
neovasculature, as was shown in mice reconstituted with
GFP-tagged bone marrow. In both models, miR-27b sig-
nificantly decreased inflammation as was evidenced by
decreased macrophage recruitment at the site of ischemic
injury. These effects were due, at least in part, to the
decreased expression of Notch ligand Dll4, PPARγ and of
inflammatory cytokines. In a contrasting approach, block-
ing miR-27b by systemic administration of an anti-miRoligonucleotide significantly decreased microvacular dens-
ity (MVD) and delayed the growth of highly aggressive
subcutaneous tumors (Levis Lung Carcinoma, LLC-1). Sur-
prisingly, treatment with anti-miR-27b also reduced the re-
cruitment and activation of tumor-associated macrophages
(TAMs). Together, our results demonstrate potential utility
of manipulating miR-27b levels in the treatment of cardio-
vascular disease and cancer as well as associated inflamma-




Lewis lung carcinoma (LLC1) and RAW 264.7 mouse
macrophage cell lines (ATCC, Manassis, VA) were
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10 % FBS and 1× penicillin/
streptomycin.
MirVana brand miRNA mimics (double-stranded oli-
gonucleotides, with star strand inactivated by chemical
modifications for maximal specificity) included negative
control (NC) and mmu-miR-27b and miR-27b inhibitor
(antagomir). All were purchased from Life Technologies
(Grand Island, NY) and used with transfection reagent
in vivo-JetPEI (Polyplus-transfection, New York, NY).
Experimental animals
FVB mice (10–12 weeks old, Jackson Laboratory, Bar
Harbor, Maine), immune-compromised athymic nude
mice (hsd:athymic nude-foxn1), immune-competent C57/
Bl6 mice (4–6 weeks old, Harlan, Madison, WI) and trans-
genic mice C57BL/6-Tg (CAG-EGFP) 1Osb/J (Jackson La-
boratory, Bar Harbor, Maine) were housed at Northwestern
University Center for Comparative Medicine and treated in
accordance with the NIH guidelines and protocols ap-
proved by Northwestern University Animal Care and Use
Committee (ACUC ASP 2012–2864).
Matrigel plug assay
Matrigel assay was performed as described previously
[29]. Ice-cold matrigel (BD Biosciences, San Jose, CA)
was supplemented with Heparin 60U/ml, with or with-
out VEGF (200 ng/ml). miR27b and NC mimic (20 μg/
mouse) were formulated with in vivo-JetPEI (PolyPlus
Transfection, France) in 5 % glucose, according to man-
ufacturer’s instructions, and added, where indicated.
Matrigel (0.4 ml/mouse) was injected subcutaneously in
the median abdominal area of anesthetized nude mice
and allowed to solidify. After 10 days, the plugs were ex-
cised and snap-frozen for further analysis.
Induction of hind-limb ischemia (HLI)
Ischemia was induced surgically as described previously
[30]. FVB mice (10–12-weeks old) were anesthetized
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Louis, MO). Ischemia was induced by ligation of the
femoral artery at the site of bifurcation, the epigastric ar-
tery and at the bifurcation of the femoral artery, and the
popliteal artery followed by the removal of the entire
femoral artery. The animals were followed for 14 days
with visual inspection and laser Doppler imaging [31].
On day 14, the animals were euthanized and the quadri-
ceps and gastrocnemius muscle harvested and frozen in
TissueTek OCT compound (Fisher).Laser doppler imaging (LDI)
Blood flow in the hind legs of anesthetized animals was
measured under standardized conditions, with Laser
Doppler Imager (Moor Instruments, UK). The mice were
kept on a heating pad (37 °C) to minimize variation be-
tween flow measurements. The perfusion ratio between
ligated and intact leg was calculated for each time point.Induction of myocardial infarction by coronary artery
ligation (CLI)
C57/Bl6 mice (10 weeks old) were anesthetized with
Avertin (250 mg/kg) and orally intubated with a 22-
gauge catheter, for artificial ventilation with a respirator
(Harvard Apparatus). A left intercostal thoracotomy was
performed and the ribs were retracted with 5–0 polypro-
pylene sutures to open the pericardium. The left anterior
descending (LAD) branch of the left coronary artery was
ligated under dissecting microscope (Leika), distal to the
bifurcation between LAD and diagonal branch with 8–0
polypropylene sutures. After positive end-expiratory pres-
sure was applied to fully inflate the lung, the chest was
closed with 7–0 polypropylene sutures [32].Physiological assessment of left-ventricular function
Trans-thoracic 2-dimensional measurements were per-
formed using a high-resolution echocardiography system
(VEVO 770™, VisualSonics Inc., Toronto, Canada) equipped
with a 30-MHz transducer. Measurements were taken14
and 28 days post-MI on mice anesthetized with a mixture
of 1.5 % isoflurane and oxygen (1 L/min). M-mode tracings
were used to measure LV wall thickness, end-systolic diam-
eter (LVESD), and end-diastolic diameter (LVEDD). Sys-
tolic and diastolic left-ventricular areas were determined by
M-mode in long-axis configuration and fractional shorten-
ing (FS) was measured at the mid-ventricular level. The
left-ventricular chamber volumes in diastole and systole
were derived from their respective measured 2D areas
using a LV volume algorithm within the Vevo770 echo soft-
ware. Cardiac ejection fraction was determined offline by
the equation: [EF = (Diastolic Volume − Systolic Volume/
Diastolic Volume) × 100 %].Irradiation of mice and bone marrow transplantation
C57/Bl6 female mice (6–8 weeks old) were subjected to
sub-lethal whole body irradiation (500 rads/mouse).
Bone marrow was isolated by flushing the femurs and
tibias of isogenic mice, Tg (CAG-EGFP) 13OsbLeySopj,
with a 26½-gauge needle and passing through a 70-um
mesh sterile filter. After 1-day rest, the mice were trans-
planted with the bone marrow cells (3 × 106 cells/mouse
in 200 μl), by tail vein injection through a 27½-gauge
needle. The recipient mice were treated with 1.6 mg/ml
Sulphametoxazole/Trimethoprim (Bristol-Meyers-Squibb,
New York, NY) in drinking water and allowed 8 weeks
recovery.
Tumor implantation
C67Bl6 mice (12–14 weeks) reconstituted with the GFP-
tagged bone marrow were injected subcutaneously in
the right hindquarters with of 0.5 × 106 Lewis Lung
Carcinoma cells (LLC1, ATCC, Manassis, VA) in 0.1 mL
PBS. When tumors reached 5 mm in diameter, animals
were randomized into groups (n = 5) and treated with
miR-27b mimic, inhibitor and negative control complexes
prepared in sterile 5 % glucose using in vivo-jetPEI
(PolyPlus Transfection, France).
Treatment of mice
After hind limb surgery or MI, mice were randomized
into groups (n ≥ 6). In HLI model, mice were treated by
intramuscular injections of miR27b and NC mimics into
the quadriceps muscle (10 μg/mouse/day, 2 injections in
a total of 50 μl, via 27-gauge needle). miRNA were for-
mulated with jetPEI in 5 % glucose. For the myocardial
infarction (MI) model, miR-27b and NC mimics formu-
lated as above were administered at the time of surgery by
intracardiac injections (10 μg/mouse, two 10 μl injections),
using a 10 μl Hamilton syringe with a 30-gauge needle.
Mice with LLC tumors (5–7 mm diameter) were random-
ized into groups (n = 5) and treated with intraperitoneal
injections of NC, miR-27b mimic or inhibitor, formulated
as above (100 μg/100 μl/mouse). At the endpoint mice
were sacrificed and tissues harvested for analysis.
Immunohistochemistry
All antibodies and dilutions used for this procedure are
listed in Table 1 below. To detect blood vessels, 5-μm
thick matrigel plug or tumor cryosections were stained with
rat anti-mouse CD31 antibody (1:100, BD Pharmingen, San
Jose, CA) followed by donkey anti-rat Rhodamine Red-X
conjugated secondary antibodies (1:1000, Jackson Immu-
noresearch). Dll4 in frozen sections was detected using
rabbit anti-mouse antibody (1:100, Abcam, Cambridge,
MA) followed by goat anti-rabbit Alexa Fluor 488 con-
jugate (Jackson Immunoresearch, West Grove, PA). The
nuclei were visualized with 4′,6-diamidine-2-phenyl
Table 1 Antibodies used in the study (immunostaining analyses)
Antibody Type Vendor Cat. no. Dilution
CD31 (rat anti-mouse) 1° BD Pharmingen, San Jose, CA 553370 10−2
Dll4 (rabbit anti-mouse) 1° Abcam, Cambridge, MA ab7280 10−2
F4/80 surface antigen (rat anti-mouse) 1° Affymetrix, Santa Clara, CA 14-4801 10−2
Green Fluorescent Protein (rabbit anti-mouse) 1° Abcam, Cambridge, MA ab6556 10−3
Smooth Muscle Actin (rabbit anti-mouse) 1° Abcam, Cambridge, MA ab5694 10−2
Collagen I (rabbit anti-mouse) 1° Abcam, Cambridge, MA ab34710 10−2
Donkey anti-rat, RR-X conjugate 2° Jackson Immuno Research, West Grove, PA 712-295-153 10−2
Goat anti-rabbit, Alexa Fluor 488 conjugate 2° Jackson Immuno Research, West Grove, PA 111545-144 10−2
Donkey anti-rabbit, Alexa Fluor 488 conjugate 2° Life Technologies, Grand Island, NY A-21206 1.5 × 10−2
Table 2 Primers used in the study
Gene Direction Sequence (5′–3′)
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anti-mouse antibody against F4/80 cell surface antigen
(1:100, Affymetrix, Santa Clara, CA) followed by donkey
anti-rat Rhodamine conjugate (Jackson Immunoresearch).
GFP on frozen sections was visualized with rabbit anti-
mouse antibody (1:1000, Abcam, Cambridge, MA) and
donkey anti-rabbit Alexa Fluor 488 conjugate (Life Tech-
nologies, Grand Island, NY). Digital images of immuno-
stained sections were obtained with Nikon Diaphot 2000
epifluorescence. Paraffin-embedded tissues were proc-
essed and stained at Northwestern University Pathology
Core to detect endothelial cell marker CD31, smooth
muscle actin (SMA), Collagen (Col) I, macrophage marker
F4/80 and with Masson Trichrome reagent to detect
fibrotic areas.
Electroporation of cells
RAW 264.7 macrophages were transfected by electro-
poration using D-032 Nucleofector device with Amaxa
Cell Line Nucleofector kit V (Lonza, Walkersville, MD)
following manufacturer’s instructions. For every 2 × 106
30 nM miR-27b mimic, inhibitor, NC RNAi or 2 μg GFP
plasmid (transfection control) were in added. After elec-
troporation, the cells were grown 48 h and total RNA
for RT-PCR was extracted as described above.
Morphometric and statistical analysis
Images were analyzed in a blinded fashion with NIS-
Elements BR software (Nikon Inc., USA). GraphPad
Prism software (Version 5.01, La Jolla, USA) was used for
statistical analyses. For quantitative traits, all datasets were
subjected to descriptive statistical analysis to establish
normality, using Kolmogorov-Smirnov and D’Agostino-
Pearson normality tests. Normally distributed datasets
were compared pairwise or as a group using 2-tailed
Student’s t test or Tukey’s multiple comparisons test.
Non-normally distributed datasets were compared using
Mann–Whitney test for single-time measurements. For
multiple time points, two-way ANOVA was used followedby Bonferroni posttest for normally distributed data and
Kruskal-Wallis for non-normal distribution. P < 0.05 was
considered significant.Quantitative real-time polymerase chain reaction (Q-PCR)
Total RNA was extracted with RNeasy isolation kit
(Qiagen, Valencia, CA), per manufacturer’s instructions.
Dll4, Spry-2, Col I and SMA were amplified with Sso
Advanced SYBR Green Supermix kit (Bio-Rad, Hercules,
CA) with the primers specific for mouse genes (Table 2).Results
miR-27b mimicry promoted de novo angiogenesis and
BMDC recruitment
We have used in vivo assay for angiogenesis in subcuta-
neous Matrigel plugs [29]. Adding miR-27b mimic to
the Matrigel clearly increased the number of CD31-
positive vascular structures at baseline, in the absence of
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giogenic response to VEGF (Fig. 1a, b).
Neovasculature can be assembled from the endothe-
lial cells formed by local proliferation of pre-existing
endothelium, or by incorporation of the circulating
precursors that originate in the bone marrow (bone
marrow derived cells, BMDCs) [33]. To assess the
contribution of the BMDCs to the pro-angiogenic
function of miR-27b we used Matrigel plug assay in
mice transplanted with GFP-tagged bone marrow from
Tg (CAG-EGFP) 13OsbLeySopj mice. miR-27b signifi-
cantly increased recruitment of GFP-positive BMDCs
to the site of VEGF-induced neovascularization (Fig. 1c, d).
However, in contrast with previously published results
[34], the majority of the GFP-positive BMDCs cells
neither assumed endothelial fate nor were incorpo-
rated in the neovessels, as was evidenced by the lack of
co-localization between GFP and the endothelial marker
CD31 (Fig. 1e).Fig. 1 miR-27b augments VEGF-induced angiogenesis and recruitment of the
with Heparin (60 U/ml) to retain growth factors, was injected in mice to genera
RNAi (NC), were added to Matrigel as indicated. The plugs were harvested and
plugs were stained for the endothelial marker, CD31 (red) and cell nuclei visuali
condition) were taken and CD31-positive vascular area measured using
whiskers; median values are shown. P value was calculated using Kruskal-Wall
were lethally irradiated and reconstituted with bone marrow (BM) harvest
6-week recovery, mice were used in Matrigel plug assay for angiogenesis,
(d) The recruitment of the GFP-positive BMDCs to the Matrigel (green fluoresc
from at least eight ×20 fields per condition are graphed as box plot with whi
Signed Rank test. Note elevated BMDC recruitment in response to miR-27b. (e
GFP-positive BMDCs (green). Note minimal co-localization between CD31 andmiR-27b enhanced angiogenesis and improves perfusion
in the ischemic hind limb
We then tested whether miR-27b similarly accelerates
angiogenesis in the ischemic muscle. Hind Limb Ischemia
(HLI) in FVB mice was induced by femoral artery ligation.
After surgery, the mice received intramuscular (IM) injec-
tions of miR-27b mimic or negative control (non-silencing
RNAi) for three consecutive days. Treatment with miR-
27b mimic significantly improved tissue vascularization,
as was shown by immunofluorescence for the endothelial
marker, CD31 (Fig. 2a-c). In agreement, miR-27b mimic
caused a statistically significant improvement in tissue
perfusion by day seven post-ligation, as measured by
Doppler Laser Imaging (DLI) (Fig. 2d, e).
miR-27b preserved angiogenesis and protected tissue
function in the infarcted heart
In the mouse model of myocardial infarction (MI) caused
by coronary artery ligation (CLI), a single application ofbone marrow -derived cells. Extracellular matrix (Matrigel) supplemented
te subcutaneous gel plugs. VEGF, miR-27b mimics (27b) or negative control
processed for analysis after 10 days. (a) Sections of cryopreserved Matrigel
zed with DAPI (blue). (b) Fluorescence images (×20, a minimum of 10 per
Elements software (Nikon). The data is presented as box plot with
is test. Note increased vascularization in the presence of miR-27b. (c) Mice
ed from mice with ubiquitous expression of actin-GFP transgene. After
as in (a). GFP-expressing BM-derived cells (BMDCs) are shown in green.
ence area) was measured using Elements software. The measurements
skers; median values are shown. P value is calculated using Wilcoxon
) Dual immunofluorescence for the endothelial marker, CD31 (red) and
GFP (yellow)
Fig. 2 miR-27b improves perfusion in murine model of critical limb ischemia. Hind limb ischemia (HLI) was induced in FVB mice by surgical
ligation of the femoral arteries on day 0. Laser Doppler scans (LDS) have been performed for each animal prior to surgery (day −1), after ligation
(day 0) to confirm the onset of ischemia, and on days 5 and 7, to assess recovery. On day 0, mice were randomly assigned to groups (n = 5) and
injected three times with negative control (RNAi) or miR-27b mimic (10 μg/injection/day, days 0–2; NC and 27b, respectively). Tissues were harvested
and processed on day 14. (a) At endpoint (day 14) calf muscles were harvested and snap-frozen for analysis. Five-μm crosswise sections were stained
for the endothelial marker, CD31 (red), to assess microvessel density (MVD). Representative photomicrographs are shown. (b, c) CD31-positive vascular
area was measured using Elements software (Nikon) on the images of at least nine fields from three independent sections (×20 objective). The data
are presented as box plots with whiskers. P values were calculated using Tukey’s Multiple Comparisons test (b) Note increased vascular area in ischemic
tissue upon miR-27 treatment (27b) compared to control (NC). (c). To correct for the baseline MVD in each animal, the ratio between ischemic (HLI)
and non-ischemic (control) limb was calculated for miR-27b and control-treated animals. P value was calculated using one-sample t test. (d) The
representative LDS images for days 0 and 7. Color scale for perfusion range is shown, with blue indicating impeded perfusion. Ischemic legs are
indicated by arrows. (e) The perfusion was quantified and normalized against control (intact) limb; mean values and S.E.M. were calculated for
each time point. P values were calculated by the Two-way RM ANOVA and Bonferroni posttest. Note progressive improvement of blood flow in
ischemic limbs in miR-27b group (27b) compared to control treated group (NC)
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vasculature as was determined by IHC for CD31, with 1.6-
fold higher MVD in the infarcted area compared to control
group (Fig. 3a, b). Improved vascularization was associated
with a significant degree of tissue protection in the animals
treated with miR-27b mimic. MiR-27b significantly allevi-
ated fibrosis, as was measured by Masson Trichrome stain-
ing (Fig. 3c, d), and Collagen 1 deposition and expression
as was determined by IHC, and RT-PCR, respectively
(Fig. 3e, h). Similar trend was observed for smooth muscle
actin (Additional file 1: Figure S1). Importantly, these
changes caused by miR-27b mimicry resulted in improved
cardiac function, with an approximately 2-fold increase in
ejection fraction over control by day 14 (Fig. 3f) and a trend
towards increased fractional shortening (Fig. 3g).
miR-27b inhibitor suppresses cancer growth and
angiogenesis
Angiogenesis is a rate-limiting factor in tumor progres-
sion. We therefore examined the effect of miR-27binhibitor on tumor angiogenesis and associated growth
rates. We used Lewis Lung carcinoma, a particularly
aggressive mouse tumor cell line, in a syngeneic sub-
cutaneous model. Systemic treatment with miR-27b in-
hibitor, 27b(I) at 5 mg/kg caused a significant reduction
of tumor weight at the endpoint (Fig. 4a-c, Additional
file 1: Figure S5). In contrast, miR-27b mimic, 27b(M)
had only moderate, albeit statistically significant effect
on tumor growth compared to control groups (untreated
mice and mice treated with control RNAi). In agreement,
treatment with anti-miR-27b significantly reduced tumor
MVD, while miR-27b had only modest effect on already
robust angiogenesis in the LLC tumors, (Fig. 4d, e).
miR-27b manipulations alter Dll4 expression in ischemic
and tumor tissue
Previous studies from our group implicated the suppres-
sion of Notch ligand, Dll4 in the pro-angiogenic action
of miR-27b [26]. In the endothelial cells, Notch signaling
interferes with tip cell fate [35]: therefore suppression of
Fig. 3 miR-27b is cardioprotective and pro-angiogenic in a mouse model of myocardial infarction (MI). MI was induced in C57Bl6 mice by ligating
left coronary artery. Negative control RNAi (NC) or miR-27b mimics were formulated with Jet-PEI and injected into cardiac muscle at the time of
surgery (10 μg/mouse). Transthoracic echocardiography was performed 14 and 28 days post-surgery and the animals were sacrificed on day 28.
(a, b) Immunohistochemistry (a) and quantitative analysis (b) of the endothelial marker, CD31, in the hearts of mice treated with NC or miR-27b.
The data is presented as boxplot with whiskers. P value was calculated by Kruskal-Wallis method. (c, d) Apical heart sections were assessed for
fibrosis using Masson-Trichrome staining. (c) Representative images of the hearts treated with NC and miR-27b mimic (27b), respectively. Arrows
point to the areas of fibrosis (blue). (d) Quantitative analysis of fibrotic areas was performed using Nikon Elements software; data is shown as dot
plot with whiskers. P value was calculated by Kruskal-Wallis method. (e) Five-μm horizontal apical sections of the hearts treated as indicated were
stained for collagen 1, for additional assessment of fibrosis. (f) Total RNA was extracted from cryopreserved tissue isolated from the infarcted areas
and expression of Collagen I (Col I) measured by real-time RT-PCR with GAPDH served as an internal control. Data is presented as dot plot with
whiskers. P value was determined using Mann–Whitney (Wilcoxon) test. (g, h) Left ventricular cardiac function, including ejection fraction (g) and
fractional shortening (h) were measured using images obtained by two-dimensional M-mode echocardiography; statistical analysis was performed
using Kruskal-Wallis test. Note a significant increase in the ejection fraction at day 14 in the hearts treated with miR-27b
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increases vascular sprouting, and miR-27b interference
should augment Dll4 and inhibit vascular sprouts. This
model has been previously confirmed in zebrafish studies.
We have ascertained the appropriate increase and decrease
of mature miR-27b levels in the target tissues of animals
treated with miR-27b mimic and inhibitor, respectively,
by real-time PCR (Additional file 1: Figures S2 and S5).
IF staining showed elevated Dll4 levels in ischemic calf
muscle, which was significantly reduced in the presence
of miR-27b mimic (Fig. 5a, b). Similar decrease in Dll4
mRNA was observed by real-time PCR in cardiac tissue
of mice treated with miR-27b mimic (Additional file 1:
Figure S3). Spry-2, another known target of miR-27b was
not significantly altered (Additional file 1: Figure S4).
In subcutaneous LLC tumors, miR-27b had disparate
effects on the total and vascular Dll4 expression. LLC
tumors showed high baseline levels of Dll4 as was mea-
sured by immunofluorescence, and these levels were
modestly but significantly increased by 27b(M) and
moderately reduced in response to 27b(I) (Fig. 5d, e). In
contrast, co-localization analysis with the vascular endo-
thelial marker, CD31, showed a significant reduction of
Dll4 specifically on tumor vasculature caused by miR-27bmimic; in agreement, miR-27b inhibitor clearly augmented
Dll4 expression by the tumor vasculature (Fig. 5f, g). The
difference in the regulation of Dll4 in the tumor cells and
vascular endothelium could be due to the tissue context,
where miR-27b could cooperate with RNA binding pro-
tein(s), such as HuR [36–38] causing mRNA stabilization
and translational activation.
miR-27b alters macrophage infiltration in ischemic and
tumor tissues
miR-27b was previously implicated in the regulation
of macrophage responses [39]. We therefore analyzed
macrophage infiltration in ischemic and tumor tissues
where miR-27b was added (mimic) or blocked (anti-miR).
miR-27b significantly attenuated macrophage infiltration
to the infarcted area, as was evidenced by IHC for
macrophage marker, F4/80 (Fig. 6a). In LLC tumors F4/
80, immunofluorescence showed no changes in macro-
phage infiltration in response to 27b(M). Surprisingly,
there was a significant decrease in F4/80 positivity upon
treatment with 27b(I).
In LPS-treated macrophages, miR-27b was previously
shown to target PPARγ and alter the downstream regu-
lation of inflammatory cytokines [39]. In agreement,
Fig. 4 miR-27b inhibition halts tumor growth and angiogenesis. Mice were implanted with subcutaneous LLC tumors in the right flank and
tumor growth was measured daily. When tumors reached 5–6 mm in diameter, the animals were treated every 2 days with intraperitoneal
injections of NC RNAi, miR-27b mimic 27b(M) or inhibitor, 27b(I) at 100 μg per mouse per injection (n = 5). After 1 week, the mice were sacrificed,
tumors harvested, weighted and cryopreserved for further analyses. (a) Gross appearance of the tumors. (b, c) Tumor volume (b) and weight (c)
at the endpoint. Data is presented as dot plot with whiskers and median values are shown. P values are calculated using Kruskal-Wallis method.
(d, e) Five-μm cryosections were stained for the endothelial marker, CD31 (D), and MVD measured as total CD31-positive area (e). The results are
presented as box plot with whiskers and P value calculated using Wilcoxon Signed Rank method. Note decreased MVD when miR-27b is inhibited,
27b(I). NT, no treatment; NC, negative control; 27b(M), miR-27b mimic; 27b(I), miR-27b inhibitor
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caused an approximately 2-fold reduction of PPARγ mRNA
(Fig. 6e). On the other hand, treatment with 27b(I) caused
a robust increase of PPARγ message (Fig. 6e), which
was consistent with decreased macrophage migration/
recruitment to the tumor (Fig. 6b, d). Importantly,
miR-27b blockade also altered macrophage polarization,
which was reflected by the alterations in relative abundance
of the M1 and M2 markers, IL12 and IL10 (Fig. 6g, f).
Discussion
Therapeutic manipulation of angiogenesis in cancer and
cardiovascular disease has been explored in pre-clinical
models with considerable success. However, toxic effects
of current anti-angiogenic therapies necessitate the de-
velopment of safer options [40], and the development of
pro-angiogenic therapies is still in progress [41–43].
miRNA regulators of angiogenesis present an attractive
therapeutic option, because they act via relatively subtle
regulation of multiple target genes within the same or
related pathways [44, 45]. Such a mechanism is more
likely to yield sufficient therapeutic benefits with lesser
toxicities, because each single target is not fully inacti-
vated. Here, we explore the possibility of therapeutic
manipulation of angiogenesis by using mimicry or inacti-
vation, as appropriate, of a pro-angiogenic microRNA,
miR-27b.
The role of miR-27b in the regulation of angiogenesis
was discovered by several groups [26–28] and itsangiogenesis-related targets identified as Dll4 [26],
Sema 6A and Sprouty-2 [26, 28, 46]. Silencing of miR-27b
leads to decreased VEGF signaling and sprouting angio-
genesis in vitro and in vivo (reviewed in [47]). Several
studies point to its role in cardiovascular development
where it is required for early venous specification of the
vascular endothelium [26] and contributes to left ventricu-
lar maturation [48] and cardiac hypertrophy [49–51]. It is
regulated by pulsatile shear stress suggesting a role in
vascular homeostasis. In agreement, simultaneous knock-
down of miR-23 and miR-27b in the miR-23/27/24 cluster
attenuated neonatal retinal angiogenesis as well as laser-
induced choroidal neovascularization [28]. However,
miR-27b is also targeted by TGF-β [52] and in vivo
overexpression results suggest potential harmful effects
in adult heart. Indeed, miR-27b silencing in pressure
overload model attenuated hypertrophy, by restoring
the expression of its other target, PPARγ [51].
Interestingly, miR-27b deficit could contribute to PAD
indirectly, via lipid metabolism. Studies support the role
of miR-27b as cholesterol hub in the liver [53]. Hepatic
miR-27b is increased in response to hyperlipidemia and,
in turn, regulates several key genes in control of lipid
metabolism (Angptl3, Gpam) [54]. Moreover, hepatic
miR-27b is downregulated and its targets elevated in
mouse models of dyslipidemia/atherosclerosis [54]. In
addition, miR-27b is decreased in differentiating adipo-
cytes and inhibits their proliferation and accumulation
via PPARγ/RXRα controlled pathways [55, 56]. This
Fig. 5 miR-27b controls of Dll4 in ischemic tissue and in vascular endothelium. Five-μm crosswise tissue sections of calf muscle or tumor tissue were
stained for Dll4, a miR-27b target (green). (a) Representative photomicrographs of Dll4 immunostaining of the calf muscle sections. (b) Total Dll4 positive
area was quantified and adjustment made for fluorescence intensity using Elements software (Nikon). Note increased Dll4 immunostaining under ischemic
conditions in animals treated with control RNAi (NC), and significant attenuation by miR-27b (27b). The data are presented as box plot with whiskers.
Median values are shown. Statistical significance and P values were determined using Wilcoxon Signed Rank test. (c, d) Sections of tumors from untreated
animals, animals treated with control RNAi (NC), miR-27b mimic (M) or inhibitor (I) were stained for Dll4 (green) and total immunofluorescence measured
in at least 8 sections/condition using Nikon Elements software. Data is presented as box plot with whiskers and mean values are shown.
Statistical significance (P values) was determined by Wilcoxon test as above. (e) Dual immunofluorescence for Dll4 (green) and CD31 (red), to
determine vascular-specific expression of Dll4. Dual positivity appears as yellow. (f) Vascular-specific Dll4 expression (a number of Dll4-positive capillary
structures/field) was measured using Nikon Elements software and statistical significance calculated as above. P values are shown
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patients.
In our short-term study, we observed increased
vascularization of the muscles of the heart and extrem-
ities subjected to ischemic stress, concomitant with
preserved tissue integrity and function, suggestive of the
therapeutic utility of miR-27b for acute treatment of
critical limb ischemia and myocardial infarction. There
are similar findings regarding other members of the
miR-23/27/24 cluster distinct from miR-27b [57]. It is
unclear, however, whether long-term application of
miR-27b and/or other miRNA from this cluster could be
harmful for cardiomyocytes and require additional
targeting to the vascular endothelium, or if there would
be long-term beneficial effects on PAD via attenuated
lipid metabolism and fat tissue development.
Earlier studies have demonstrated the ability of miR-27b
to enhance/restore angiogenic function of the BMDCs in
diabetic mice (Db/Db), causing accelerated wound healing[58]. Similarly, we observed the increased recruitment of
GFP-tagged bone marrow derived cells to the vasculature.
However, the lack of conversion of myeloid BMDCS to
the endothelial (CD31-positive) phenotype in vivo
suggests that the majority of BMDCs recruited in
response to miR-27b treatment have an accessory role
where they serve as the source of pro-angiogenic and/or
survival factors for the neovasculature.
In cancer, the role of miR-27b is controversial, with
studies lending support to its tumor-promoting and
tumor-suppressive roles. miR-27b has been identified as
a classical oncomir in cell-based assays [59] and its
elevated expression is associated with poor prognosis,
chemoresistance and metastasis in carcinomas of the
ovary and the breast [60] and in castrate-resistant prostate
cancer [61]. miR-27b is also upregulated in glioma where
it promotes tumor growth and invasion. Consistent with
pro-oncogenic role, it is upregulated by Her2 oncogene
and by epidermal growth factor [62] and repressed by
Fig. 6 miR-27b regulates inflammatory response in ischemic and tumor tissue. (a, b) IHC and IF for F4/80 of tissue sections harvested from HLI
model (a) and LLC tumors treated as indicated. Cell nuclei are visualized with DAPI (blue). (c-d) quantification of the cells positive for macrophage
marker, F4/80, (c) Macrophages were counted using ImageJ software (National Institutes of Health). Data is presented as box plot with whiskers
and P values calculated using Mann–Whitney method. (d) Macrophages were counted using “object count” function of Nikon Elements software
and statistical analysis performed using Wilcoxon test as above. (e-g) Cultured macrophages (RAW 264.7) were electroporated with negative control RNAi,
miR-27b mimic (M) and inhibitor (I). Gene expression was measured by real-time PCR with L19 and beta macroglobulin as internal controls. PPARγ (e), a
miR-27b target, and inflammatory chemokines IL-10 (f) and IL-12 (g) were assessed by real-time RT-PCR and normalized against untreated control (NT no
treatment). The results of three independent experiments are pooled together. Statistical significance was assessed by Wilcoxon Signed Rank test, as above
Veliceasa et al. Vascular Cell  (2015) 7:6 Page 10 of 13Ink4A [63, 64] in breast and pancreatic cancer. On the
other hand, the 23/27b cluster and miR-27b are downreg-
ulated and ascribed anti-tumorigenic roles in the cell lines
derived from the tumors of bladder, prostate and colon
[39, 61, 65, 66]. Thus the role of miR-27b in cancer pro-
gression is likely context-dependent. Our findings suggest
that miR-27b has different effects on tumor cells and the
cells of tumor microenvironment as is evidenced by its
disparate effect on Dll4 expression in the tumor and
tumor vasculature. Our findings suggest that the use of
miR-27b inhibitors may be feasible in the context of
personalized of cancer patients care.
Previous studies indicate that miR-27b contributes
towards inflammatory processes by destabilization of
PPARγ mRNA and protein [39]. On the other hand, it
can block inflammatory responses by targeting NF-κB
[67] or TGF-β target, Gremlin-1 [52]. In contrast with
published studies, PPARγ expression in cultured macro-
phages was only modestly affected by mir-27b mimicry,
however, it was significantly upregulated by miR-27b
inhibitor. On the other hand, miR-27b altered cytokineprofile of the cultured macrophages with increased
IL-10 and decreased IL-12 levels suggestive of alternative
(non-inflammatory) mode of activation. These findings
suggest that miR-27 inhibitors may have beneficial
effects in cancer setting by blocking the recruitment and
activation of tumor-associated macrophages. The re-
duced inflammatory infiltrates in ischemic tissue may be
secondary to anti-fibrotic action of miR-27b. Alterna-
tively, they could be due to the down-modulation of the
pro-inflammatory NF-κB. Since miR-27b itself is
repressed by TGF-β [68], its reconstitution with mimics
may be especially pertinent in the context of inflamma-
tion and fibrosis.
Together, our findings demonstrate potential utility of
manipulating miR-27b levels in cardiovascular disease
and cancer and confirm its targets as Dll4/Notch axis,
PPARγ and its downstream effectors.
Conclusions
The main non-surgical therapy for ischemic disease in-
volves mechanical stents to maintain blood flow through
Veliceasa et al. Vascular Cell  (2015) 7:6 Page 11 of 13the diseased vessels. The use of drug-eluting stents was
not yet successful. Several experimental strategies aim to
improve vascularization in the lower extremities and in
the heart by promoting the formation of collateral ves-
sels. They employ stem cell and gene therapies. In stem
cell based approaches, induced pluripotent stem cells or
bone marrow monocytes are used to enhance local
angiogenesis. Gene therapy approaches to enhance local
expression of several key growth factors, including VEGF,
bFGF and HGF, are subject to the common limitations of
gene therapies. None of these approaches have yet reached
clinic. We offer targeting the miR-27b-regulated pathways
with miR-27b-based drugs for the treatment of cardiovas-
cular disease. Manipulations of microRNA offer safer and
more effective alternative to gene therapy. In addition,
local use of oligonucleotide mimics of miR-27b facilitates
the recruitment of endogenous bone marrow-derived
stem cells to the newly forming vasculature at the target
site. Thus we provide an alternative to cell-based car-
diovascular therapies.
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